Aprotinin has direct platelet protective properties: fact or fiction?

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Cardiothoracic and Vascular Anesthesia

• Publication date

  1999-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1053-0770(99)90206-9PMID 10468247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelet protection in coronary artery surgery: benefits of heparin-coated circuits and high-dose aprotinin therapy.

  1999cited by this paper
• Platelet function during cardiac surgery and cardiopulmonary bypass with low-dose aprotinin.

  1999cited by this paper
• The platelet thrombin receptor and postoperative bleeding.

  1998cited by this paper
• In Vitro Hypothermia Enhances Platelet GPIIb‐IIIa Activation and P‐Selectin Expression

  1998cited by this paper
• Aprotinin complements heparin bonding in an in vitro model of cardiopulmonary bypass

  1998cited by this paper
• Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass.

  1997cited by this paper
• Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass.

  1997cited by this paper
• The Effects of Heparinase 1 and Protamine on Platelet Reactivity

  1997cited by this paper
• Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations.

  1996cited by this paper
• Effect of heparin on fibrinolytic activity and platelet function in vivo.

  1996cited by this paper
• Aprotinin improves hemostasis after cardiopulmonary bypass better than single-donor platelet concentrate.

  1995cited by this paper
• Platelet activation in whole blood by artificial surfaces: identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events.

  1995cited by this paper
• Platelet activation in warm and cold heart surgery.

  1995cited by this paper
• Reversible Inhibition of Human Platelet Activation by Hypothermia In Vivo and In Vitro

  1994cited by this paper
• At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects.

  1994cited by this paper
• Aprotinin reduces cardiopulmonary bypass‐induced blood loss and inhibits fibrinolysis without influencing platelets

  1993cited by this paper
• Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery.

  1993cited by this paper
• Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery

  1993cited by this paper
• Platelet function in cardiac surgery: influence of temperature and aprotinin.

  1993cited by this paper
• Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass.

  1992cited by this paper
• High-dose heparin suppresses platelet alpha granule secretion.

  1992cited by this paper
• Temperature dependence of plasmin-induced activation or inhibition of human platelets.

  1991cited by this paper
• Modulation of platelet surface adhesion receptors during cardiopulmonary bypass.

  1991cited by this paper
• The effect of protamine sulfate on platelet function.

  1988cited by this paper
• Hypothermia-induced reversible platelet dysfunction.

  1987cited by this paper
• Plasmin inhibition of platelet function and of arachidonic acid metabolism.

  1985cited by this paper

• Point-of-care viscoelastic coagulation assessment in healthy dogs during the perianesthetic period

  2021cites this paper
• Does aprotinin preserve platelets in children with acyanogenic congenital heart disease undergone surgery with cardiopulmonary bypass?

  2009cites this paper
• Aprotinina preserva plaquetas em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea? Does aprotinin preserve platelets in children with acyanogenic congenital heart disease undergone surgery with cardiopulmonary bypass?

  2009cites this paper
• CHAPTER 59 – Cardiopulmonary Bypass

  2007cites this paper
• Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage.

  2005cites this paper
• Cardiopulmonary Bypass-Associated Coagulopathies and Prophylactic Therapy

  2004cites this paper
• Biochemistry of serine protease inhibitors and their mechanisms of action: a review.

  2003cites this paper
• No benefit of intraoperative whole blood sequestration and autotransfusion during coronary artery bypass grafting: results of a randomized clinical trial.

  2003cites this paper